Keycept S 360 Tablet contains Mycophenolate sodium 360 mg, an immunosuppressive agent primarily indicated for the prevention of organ transplant rejection. Mycophenolate sodium acts by selectively inhibiting inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanine nucleotides, thereby suppressing the proliferation of T and B lymphocytes, which are critical in the immune response. This mechanism helps reduce the risk of acute rejection episodes in patients undergoing renal, cardiac, or hepatic transplantation. Keycept S 360 is typically administered as part of a combination immunosuppressive regimen alongside corticosteroids and calcineurin inhibitors to achieve optimal efficacy. The drug is absorbed in the gastrointestinal tract and undergoes hepatic metabolism. Common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain, as well as hematological abnormalities like leukopenia and anemia. Regular monitoring of blood counts and renal function is recommended during therapy. Due to its immunosuppressive action, patients are at increased risk of infections and should be advised accordingly. Keycept S 360 should be used under strict medical supervision with appropriate dose adjustments based on clinical response and tolerability.